← Back to Search

Stem Cell Therapy

Stem Cell Therapy for Central Retinal Vein Occlusion (TRUST Trial)

Phase 1 & 2
Waitlist Available
Led By Susanna S Park, MD, PhD
Research Sponsored by The Emmes Company, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

TRUST Trial Summary

This trial is testing whether a stem cell therapy can improve vision in people with central retinal vein occlusion. Half the participants will receive the therapy immediately, and the other half will receive it 6 months later.

Eligible Conditions
  • Central Retinal Vein Occlusion

TRUST Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility of the Stem Cell Therapy
Incidence and Severity of Ocular and Systemic Adverse Events
Secondary outcome measures
Change in % Reduced Sensitivity
Change in Area of Non-perfusion within ETDRS Grid
Change in Area of Non-perfusion within Networc Grid
+17 more

TRUST Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Immediate Cellular Therapy / Deferred Sham TherapyActive Control2 Interventions
At baseline: Bone marrow aspiration followed by intravitreal injection of CD34+ cells. At 6 months: Sham bone marrow aspiration and sham intravitreal injection.
Group II: Immediate Sham Therapy / Deferred Cellular TherapyPlacebo Group2 Interventions
At baseline: Sham bone marrow aspiration followed by sham intravitreal injection. At 6 months: Bone marrow aspiration followed by intravitreal injection of CD34+ cells.

Find a Location

Who is running the clinical trial?

University of California, DavisOTHER
910 Previous Clinical Trials
4,706,975 Total Patients Enrolled
National Eye Institute (NEI)NIH
546 Previous Clinical Trials
1,401,912 Total Patients Enrolled
The Emmes Company, LLCLead Sponsor
145 Previous Clinical Trials
1,051,475 Total Patients Enrolled

Media Library

Autologous Bone Marrow CD34+ Stem Cells (Stem Cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03981549 — Phase 1 & 2
Central Retinal Vein Occlusion Research Study Groups: Immediate Cellular Therapy / Deferred Sham Therapy, Immediate Sham Therapy / Deferred Cellular Therapy
Central Retinal Vein Occlusion Clinical Trial 2023: Autologous Bone Marrow CD34+ Stem Cells Highlights & Side Effects. Trial Name: NCT03981549 — Phase 1 & 2
Autologous Bone Marrow CD34+ Stem Cells (Stem Cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03981549 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does this clinical trial hope to achieve?

"The main aim of this 6-month clinical trial is to evaluate the feasibility of stem cell therapy. Secondary outcomes that will be measured include changes in non-perfusion areas within different grids, as well as the integrity of the foveal avascular zone."

Answered by AI

How many volunteers will be enrolled in this experiment?

"The listing on clinicaltrials.gov reveals that this trial is open for recruitment and has been since October 22nd, 2019. The study will take place at a single site and require 20 participants in total."

Answered by AI

Are there any current vacancies for this clinical trial?

"The study, which is still recruiting patients according to clinicaltrials.gov, was originally posted on October 22nd 2019. The listing was last updated on August 12th, 2022."

Answered by AI

Who else is applying?

What state do they live in?
Illinois
How old are they?
18 - 65
What site did they apply to?
Department of Ophthalmology & Vision Science, University of California Davis Eye Center
What portion of applicants met pre-screening criteria?
Met criteria

How responsive is this trial?

Most responsive sites:
  1. Department of Ophthalmology & Vision Science, University of California Davis Eye Center: < 24 hours
Average response time
  • < 1 Day
Typically responds via
Phone Call
Email
~3 spots leftby Apr 2025